Candesartan

Generic Name
Candesartan
Brand Names
Atacand, Atacand Hct
Drug Type
Small Molecule
Chemical Formula
C24H20N6O3
CAS Number
139481-59-7
Unique Ingredient Identifier
S8Q36MD2XX
Background

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...

Associated Conditions
Hypertension, NYHA Functional Class II-IV Heart Failure
Associated Therapies
-
Clinical Trials
Related News

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

First Posted Date
2023-04-24
Last Posted Date
2024-08-06
Lead Sponsor
University of California, San Francisco
Target Recruit Count
672
Registration Number
NCT05826912
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Post-traumatic Headache Multidisciplinary Study

First Posted Date
2022-04-14
Last Posted Date
2022-04-14
Lead Sponsor
Danish Headache Center
Target Recruit Count
100
Registration Number
NCT05328635
Locations
🇩🇰

Danish Headache Center, Glostrup, Denmark

Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

Phase 3
Recruiting
Conditions
Cardiomyopathy, Dilated
Interventions
Drug: Candesartan
First Posted Date
2022-04-11
Last Posted Date
2024-11-07
Lead Sponsor
Cristina Avendaño Solá
Target Recruit Count
320
Registration Number
NCT05321875
Locations
🇪🇸

Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

First Posted Date
2021-11-16
Last Posted Date
2023-09-15
Lead Sponsor
University of Sydney
Target Recruit Count
49
Registration Number
NCT05122182
Locations
🇮🇳

DM Wayanad Institute of Medical Sciences, Meppadi, India

🇮🇳

Sterling Hospital, Nigdi, India

🇮🇳

Jivanrekha Multi-Speciality Hospital, Pune, India

and more 7 locations

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

First Posted Date
2020-10-28
Last Posted Date
2023-02-16
Lead Sponsor
University of British Columbia
Target Recruit Count
341
Registration Number
NCT04606563
Locations
🇨🇦

Royal Jubilee Hospital, Nanaimo, British Columbia, Canada

🇨🇦

St Paul's Hospital, Vancouver, British Columbia, Canada

🇨🇦

The Ottawa Hospital, Ottawa, Ontario, Canada

and more 10 locations

Candesartan as an Adjunctive Treatment for Bipolar Depression

Early Phase 1
Withdrawn
Conditions
Bipolar Disorder Depression
Interventions
Drug: Candesartan
Drug: Placebo
First Posted Date
2020-06-16
Last Posted Date
2022-04-27
Lead Sponsor
The University of Texas Health Science Center, Houston
Registration Number
NCT04430959
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

First Posted Date
2020-06-12
Last Posted Date
2020-06-12
Lead Sponsor
Samsung Medical Center
Target Recruit Count
136
Registration Number
NCT04429633
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

First Posted Date
2020-04-17
Last Posted Date
2021-03-02
Lead Sponsor
Medical University of Vienna
Target Recruit Count
500
Registration Number
NCT04351724
Locations
🇦🇹

Medical University of Innsbruck, Innsbruck, Tirol, Austria

🇦🇹

Wilhelminenspital, Vienna, Austria

🇦🇹

SMZ Ost Donauspital, Vienna, Austria

and more 6 locations

CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study

Completed
Conditions
Migraine
Head Pain
Interventions
Drug: Candesartan
First Posted Date
2019-10-24
Last Posted Date
2022-12-19
Lead Sponsor
Hospital Clínico Universitario de Valladolid
Target Recruit Count
85
Registration Number
NCT04138316
Locations
🇪🇸

Hospital Clínico Universitario Valladolid, Valladolid, Spain

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

First Posted Date
2019-02-20
Last Posted Date
2022-05-10
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
127
Registration Number
NCT03847506
Locations
🇰🇷

Bundang Seoul National University Hospital, Gyeonggi-do, Seongnam-si, Bundang-gu, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy